Despite that the availability of new therapeutic options has expanded the multiple sclerosis
(MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy …

Using combined endpoints to define no evident disease activity (NEDA) is becoming
increasingly common when setting targets for treatment outcomes in multiple sclerosis (MS) …

Background and Objectives To estimate the proportions of patients with relapsing-remitting
multiple sclerosis who despite achieving the no evidence of disease activity-3 (NEDA-3) …

The increasing number of disease‐modifying treatments available for multiple sclerosis has
broadened treatment options for patients, but also challenges clinicians to select the best …

Background No evidence of disease activity (NEDA; defined as no 12-week confirmed
disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 …

Background Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was
demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with …

A combined endpoint measure to define no evidence of disease activity (NEDA) is becoming
increasingly appealing in the treatment of multiple sclerosis (MS). Initial efforts using a 3 …

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous
system, and the most common cause of nontraumatic disability in young adults. Most …

Objective This study aimed to define the minimal evidence of disease activity (MEDA) during
treatment that can be tolerated without exposing patients with relapsing-remitting multiple …

Background and Objectives We conducted a systematic review and meta-analysis to
evaluate the relationship between no evidence of disease activity (NEDA) and no long-term …